Who are Standard diuretic therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): olmesartan medoxomil-hydrochlorothiazide, Benicar, TORSEMIDE, Zestril, Lozol, Bumex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/standard-diuretic-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Standard diuretic therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Standard diuretic therapy (Standard diuretic therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Diuretic. Area: Cardiovascular.

marketed Diuretic Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Standard diuretic therapy (Standard diuretic therapy) — University of Parma. Standard diuretic therapy increases urine output and reduces fluid volume in the body by inhibiting sodium and water reabsorption in the kidneys.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Standard diuretic therapy TARGET	Standard diuretic therapy	University of Parma	marketed	Diuretic
olmesartan medoxomil-hydrochlorothiazide	OLMESARTAN	Cosette	marketed	Thiazide Diuretic [EPC]		2019-01-01
Benicar	OLMESARTAN MEDOXOMIL	Cosette	marketed	Thiazide Diuretic [EPC]	Type-1 angiotensin II receptor	2002-01-01
TORSEMIDE	TORSEMIDE		marketed	Loop Diuretic [EPC]	Na+/K+/2Cl- carrier system	1993-01-01
Zestril	lisinopril	Generic (originally Merck/AstraZeneca)	marketed	Thiazide Diuretic [EPC]	Angiotensin-converting enzyme, Angiotensin-converting enzyme	1987-12-29
Lozol	INDAPAMIDE		marketed	Thiazide-like Diuretic [EPC]	Carbonic anhydrase 7	1983-01-01
Bumex	BUMETANIDE		marketed	Loop Diuretic [EPC]	Solute carrier family 12 member 1	1983-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-10-06 — TORSEMIDE · 10154963 · Formulation · US
2035-11-06 — Zestril · 10039800 · Method of Use · US
2035-11-06 — Zestril · 10406199 · Method of Use · US
2035-11-06 — Zestril · 12433931 · Method of Use · US
2035-11-06 — Zestril · 10265370 · Formulation · US
2035-11-06 — Zestril · 9463183 · Formulation · US
2035-11-06 — Zestril · 11179434 · Formulation · US
2035-11-06 — Zestril · 9814751 · Formulation · US
2035-11-06 — Zestril · 9616096 · Method of Use · US
2035-11-06 — Zestril · 11771733 · Formulation · US
2035-11-06 — Zestril · 12186360 · Formulation · US
2035-11-06 — Zestril · 12128083 · Formulation · US
2035-11-06 — Zestril · 10940177 · Formulation · US
2040-12-04 — Bumex · 11260038 · Method of Use · US
2040-12-04 — Bumex · 11123319 · Formulation · US
2040-12-04 — Bumex · 12329731 · Formulation · US

Sponsor landscape (Diuretic class)

Fundación EPIC · 1 drug in this class
Medtronic BRC · 1 drug in this class
University of Parma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Standard diuretic therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-diuretic-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab